Several lines of study suggest that peripheral metabolism of amyloid beta (Aß) is associated with risk for Alzheimer disease (AD). In blood, greater than 90% of Aß is complexed as an apolipoprotein, raising the possibility of a lipoprotein-mediated axis for AD risk. In this study, we report that genetic modification of C57BL/6J mice engineered to… Continue reading Synthesis of human #amyloid restricted to #liver results in an #Alzheimer disease–like neurodegenerative phenotype
Category: Hepatology
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
AMP kinase (AMPK) is an energy sensor implicated in regulation of lipid metabolism, inflammation, and insulin sensitivity. We aimed to assess efficacy and safety of PXL770, a novel direct AMPK activator, in patients with non-alcoholic fatty liver disease (NAFLD). MethodsSTAMP-NAFLD, a randomised, double-blind, placebo-controlled phase 2a study, was done across 15 US clinical sites. Patients… Continue reading Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Role and Mechanism of Gut #Microbiota in Human #Disease
The human gut microbiome is a huge microbial community that plays an irreplaceable role in human life. With the further development of research, the influence of intestinal flora on human diseases has been gradually excavated. Gut microbiota (GM) dysbiosis has adverse health effects on the human body that will lead to a variety of chronic… Continue reading Role and Mechanism of Gut #Microbiota in Human #Disease
#Elastography is unable to exclude #cirrhosis after sustained virological response in #HCV-infected patients with advanced chronic liver disease
Liver fibrosis and transient elastography (TE) correlation in hepatitis C virus (HCV)-infected patients with compensated advanced chronic liver disease (cACLD) after sustained virological response (SVR) is unknown. AimsTo evaluate TE accuracy at identifying cirrhosis 3 years after HCV-eradication. MethodsProspective, multi-centric study including HCV-cACLD patients before direct-acting antivirals (DAA). Diagnostic accuracy of TE (area under ROC,… Continue reading #Elastography is unable to exclude #cirrhosis after sustained virological response in #HCV-infected patients with advanced chronic liver disease
#Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a high‐fat diet. We have now performed a regression study with cysteamine, which is… Continue reading #Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
#Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
Pradefovir is a liver-targeted prodrug of adefovir, a nucleotide analog with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30mg, 45mg, 60mg, and 75mg) versus tenofovir disoproxil fumarate (TDF; 300mg) and aimed to identify the most appropriate dose of pradefovir for the… Continue reading #Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial
Plasma Levels of #Homocysteine is Associated with Liver #Fibrosis in Health Check-Up Population
Studies have shown a link between homocysteine (Hcy) and heart diseases, kidney diseases, cerebrovascular diseases, liver diseases, and other pathological conditions. However, the relationship between Hcy and liver fibrosis (LF) is unclear. Here, we studied the link between plasma Hcy concentration and LF. Methods: We determined and recorded the plasma Hcy concentration, general biochemical parameters,… Continue reading Plasma Levels of #Homocysteine is Associated with Liver #Fibrosis in Health Check-Up Population
#NONALCOHOLIC FATTY LIVER DISEASE-RELATED RISK OF #CARDIOVASCULAR DISEASE AND OTHER CARDIAC COMPLICATIONS
Nonalcoholic fatty liver disease (NAFLD) affects approximately ~25% of the global adult population. The aim of this narrative review is to describe the associations between NAFLD and cardiovascular disease (CVD), arrhythmias, cardiac conduction defects, myocardial remodelling and heart failure. We also discuss the potential mechanisms that mediate or attenuate the strength of these associations, and… Continue reading #NONALCOHOLIC FATTY LIVER DISEASE-RELATED RISK OF #CARDIOVASCULAR DISEASE AND OTHER CARDIAC COMPLICATIONS
The changing characteristics of patients infected with chronic hepatitis #C virus from 2014 to 2019: Real-world data from the German #Hepatitis C-Registry (DHC-R)
The number of patients diagnosed with hepatitis C virus (HCV) is markedly higher than the number initiating treatment indicating gaps in the care cascade, likely centered around reaching at-risk populations. Understanding changing characteristics of patients with HCV allows for targeted programs that increase linkage to care. We investigated changes in demographic and clinical characteristics of… Continue reading The changing characteristics of patients infected with chronic hepatitis #C virus from 2014 to 2019: Real-world data from the German #Hepatitis C-Registry (DHC-R)
